¼¼°èÀÇ °£¾Ï Ä¡·áÁ¦ ½ÃÀå
Liver Cancer Drugs
»óǰÄÚµå : 1514208
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 277 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀº 2030³â±îÁö 93¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 28¾ï ´Þ·¯·Î Æò°¡µÈ ¼¼°èÀÇ °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö ºÐ¼® ±â°£¿¡ CAGR 18.4%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 93¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠǥÀû ¾à¹° Ä¡·á´Â CAGR 18.5%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á ½Ã 51¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. È­Çпä¹ý ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ÀÇ CAGR·Î 16.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 7¾ï 6,380¸¸ ´Þ·¯, Áß±¹Àº CAGR 24.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀº 2023³â 7¾ï 6,380¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2023³âºÎÅÍ 2030³â±îÁö CAGR 24.4%·Î Àü¸ÁµÇ¸ç, 2030³â±îÁö ½ÃÀå ±Ô¸ð 23¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 13.6%¿Í 15.7%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 14.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°£¾Ï Ä¡·áÁ¦-ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ

°£¾Ï Ä¡·áÁ¦¿¡´Â °£¼¼Æ÷¾Ï(HCC) ¹× °£ÀÇ ´Ù¸¥ ¾Ç¼º Á¾¾çÀÇ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÑ ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¿ø¹ß¼º °£¾Ï¿¡¼­ °¡Àå ÈçÇÑ °£¼¼Æ÷¾ÏÀº BÇü °£¿°°ú CÇü °£¿°, ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH), °£°æº¯ µîÀÇ ¸¸¼º °£ Áúȯ¿¡ µû¶ó ¹ßº´ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. °£ÀÇ ±â´ÉÀº º¹ÀâÇϰí ü³»ÀÇ ´ë»ç °úÁ¤¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí Àֱ⠶§¹®¿¡ °£¾ÏÀÇ Ä¡·á´Â ¿ª»çÀûÀ¸·Î ¾î·Á¿î °úÁ¦¿´½À´Ï´Ù. ¼ö¼ú ¹× °æµ¿¸Æ È­ÇÐ »öÀü ¿ä¹ý(TACE)°ú °°Àº ±¹¼Ò ¿ä¹ýÀ» Æ÷ÇÔÇÑ ÀüÅëÀûÀÎ Ä¡·á¹ýÀº Àü½Å Ä¡·áÀÇ ÃâÇöÀ¸·Î º¸¿ÏµÇ¾ú½À´Ï´Ù. ¼Ò¶óÆä´Õ ¹× ·½¹ÙƼ´Õ°ú °°Àº Ç¥Àû ¿ä¹ýÀº Á¾¾ç ¼ºÀå ¹× Ç÷°ü½Å»ý¿¡ °ü¿©Çϴ ƯÁ¤ °æ·Î¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á ÁøÇà °£¾ÏÀÇ °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº »ýÁ¸¿¡ Å« ÀÌÀÍÀ» Á¦°øÇÏÁö¸¸, ȯÀÚÀÇ QOL¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ºÎÀÛ¿ëÀ» ¼ö¹ÝÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.

ÃÖ±Ù ¸é¿ª¿ä¹ýÀÌ °£¾Ï Ä¡·áÀÇ È¹±âÀûÀÎ Á¢±Ù¹ýÀ¸·Î ºÎ»óÇØ ¿Ô½À´Ï´Ù. Æèºê·Ñ¸®ÁÖ¸¿À̳ª ´Ïº¼·ç¸¿ µîÀÇ ¸é¿ª üũÆ÷ÀÎÆ® ¾ïÁ¦Á¦´Â ¾Ï¼¼Æ÷¿¡ ´ëÇÑ ½ÅüÀÇ ¸é¿ª¹ÝÀÀÀ» Áõ°­ÇÏ´Â °ÍÀ¸·Î À¯¸Á½ÃµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·áÁ¦´Â ¸é¿ª°èÀÇ È°µ¿À» ÀúÇØÇÏ´Â ´Ü¹éÁúÀ» Â÷´ÜÇÔÀ¸·Î½á T¼¼Æ÷°¡ ¾Ï¼¼Æ÷¸¦ º¸´Ù È¿°úÀûÀ¸·Î °ø°ÝÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¶ÇÇÑ, ¸é¿ª¿ä¹ýÀ» Ç¥ÀûÄ¡·á ¹× ±âŸ Ä¡·á¹ý°ú ÅëÇÕÇÏ´Â º´¿ë¿ä¹ýµµ ÀÓ»ó½ÃÇè¿¡¼­ Àû±ØÀûÀ¸·Î °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¾ÆÅ×Á¹¸®ÁÖ¸¿°ú º£¹Ù½ÃÁÖ¸¿ÀÇ º´¿ë ¿ä¹ýÀº ÀüÅëÀûÀÎ ´ÜÀÏ ¿ä¹ý¿¡ ºñÇØ Ä¡·á ¼ºÀû °³¼±À» º¸¿©ÁÝ´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â º¸´Ù °³º°È­µÈ È¿°úÀûÀÎ Ä¡·á¿ä¹ýÀ¸·ÎÀÇ ½ÃÇÁÆ®¸¦ °­Á¶ÇÏ´Â °ÍÀ̸ç, »ýÁ¸±â°£ÀÇ ¿¬Àå»Ó¸¸ ¾Æ´Ï¶ó °£¾Ï ȯÀÚÀÇ ÀüüÀûÀÎ QOLÀÇ Çâ»óÀ» ¸ñÇ¥·Î ÇÏ´Â °ÍÀÔ´Ï´Ù.

°£¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ù°, ƯÈ÷ °£¿° °¨¿°À̳ª NASHÀÇ À¯º´·üÀÌ ³ôÀº Áö¿ª¿¡¼­ °£¾ÏÀÇ ÀÌȯÀ²ÀÌ »ó½ÂÇÏ¿© È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. µÑ°, ÀǾàǰ °³¹ß°ú À¯Àüü ¿¬±¸ÀÇ ±â¼úÀû Áøº¸´Â ½Å±Ô Ä¡·á Ç¥ÀûÀÇ ¹ß°ß°ú º¸´Ù È¿°úÀûÀÎ ¾à¹°ÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼Â°, ¸é¿ª¿ä¹ý ¹× Ç¥ÀûÄ¡·áÀÇ ¼º°øÀÌ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ ºÒ·¯µé¿© °æÀïÀûÀ̰í Çõ½ÅÀûÀÎ ½ÃÀåȯ°æÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ ´ç±¹ÀÌ È¹±âÀûÀÎ Ä¡·áÁ¦¿¡ ´ëÇÑ ½Å¼ÓÇÑ ½ÂÀÎÀ» ¹Þ°í Àֱ⠶§¹®¿¡ ȯÀÚ¿¡°Ô »õ·Î¿î Ä¡·á¹ýÀ» Á¦°øÇÏ´Â °ÍÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ½Ã³ÊÁö È¿°ú¿Í Ä¡·á ¼ºÀû °³¼±À» °¡Á®¿À´Â º´¿ë ¿ä¹ýÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¶±â Áø´Ü ¹× °í±Þ Ä¡·á ¿É¼ÇÀÇ ÀÌÁ¡¿¡ ´ëÇÑ °Ç°­ °ü¸® Á¦°ø¾÷ü¿Í ȯÀÚÀÇ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½Å¾à ä¿ë·üÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ½ÅÈï±¹ÀÇ °Ç°­ °ü¸® ÀÎÇÁ¶ó È®Ãæ°ú ¼±Áø ÀÇ·á¿¡ ´ëÇÑ ¾×¼¼½º°¡ ½ÃÀå ¼ºÀåÀÇ »õ·Î¿î ±âȸ¸¦ ³º°í, Çõ½ÅÀûÀÎ °£¾Ï Ä¡·á°¡ º¸´Ù ¸¹Àº ȯÀÚ¿¡°Ô Àü´ÞµÉ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀÌ Á¾ÇÕÀûÀ¸·Î °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ °ßÁ¶ÇÑ È®´ë¿Í ¿ªµ¿ÀûÀÎ ÁøÈ­¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 52°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Liver Cancer Drugs Market to Reach US$9.3 Billion by 2030

The global market for Liver Cancer Drugs estimated at US$2.8 Billion in the year 2023, is expected to reach US$9.3 Billion by 2030, growing at a CAGR of 18.4% over the analysis period 2023-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 16.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$763.8 Million While China is Forecast to Grow at 24.4% CAGR

The Liver Cancer Drugs market in the U.S. is estimated at US$763.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 24.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.6% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.

Liver Cancer Drugs - Key Trends and Drivers

Liver cancer drugs encompass a diverse range of therapeutic options aimed at treating hepatocellular carcinoma (HCC) and other malignancies of the liver. HCC, the most common type of primary liver cancer, often develops in the context of chronic liver diseases such as hepatitis B and C infections, non-alcoholic steatohepatitis (NASH), and cirrhosis. The treatment landscape for liver cancer has historically been challenging due to the complexity of the liver’s function and its vital role in the body’s metabolic processes. Traditional approaches, including surgery and localized therapies like transarterial chemoembolization (TACE), have been complemented by the advent of systemic treatments. Targeted therapies, such as sorafenib and lenvatinib, have been integral in managing advanced liver cancer by inhibiting specific pathways involved in tumor growth and angiogenesis. These drugs have provided significant survival benefits, although they are often associated with considerable side effects that can impact patients' quality of life.

In recent years, immunotherapy has emerged as a groundbreaking approach in the treatment of liver cancer. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown promise in enhancing the body’s immune response against cancer cells. These therapies work by blocking proteins that inhibit immune system activity, thus allowing T-cells to attack cancer cells more effectively. Additionally, combination therapies that integrate immunotherapies with targeted treatments or other modalities are being actively explored in clinical trials. The combination of atezolizumab and bevacizumab, for example, has demonstrated improved outcomes compared to traditional monotherapies. These advancements underscore a shift towards more personalized and effective treatment regimens, which not only aim to extend survival but also improve the overall quality of life for patients with liver cancer.

The growth in the liver cancer drugs market is driven by several factors. Firstly, the rising incidence of liver cancer, particularly in regions with high prevalence of hepatitis infections and NASH, has increased the demand for effective treatments. Secondly, technological advancements in drug development and genomic research have facilitated the discovery of novel therapeutic targets and the development of more effective drugs. Thirdly, the success of immunotherapies and targeted therapies has attracted significant investment in research and development, fostering a competitive and innovative market environment. Additionally regulatory agencies are providing accelerated approvals for breakthrough therapies, which helps expedite the availability of new treatments to patients. The increasing adoption of combination therapies, which offer synergistic effects and improved outcomes, further drives market growth. Furthermore, heightened awareness among healthcare providers and patients about the benefits of early diagnosis and advanced treatment options has led to a higher adoption rate of new drugs. Lastly, the expansion of healthcare infrastructure and access to advanced medical treatments in emerging economies is creating new opportunities for market growth, ensuring that innovative liver cancer therapies reach a broader patient population. These factors collectively contribute to the robust expansion and dynamic evolution of the liver cancer drugs market.

Select Competitors (Total 52 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â